ArticleUrology research & practice2026
Multicenter Study on Integrating Prostate Magnetic Resonance Imaging with Prostate-Specific Antigen Density for Risk-Adapted Biopsy Strategy in a South Korean Cohort.
Article in Urology research & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCombining Prostate Imaging-Reporting and Data System (PI-RADS) with prostate-specific antigen density (PSAD) may improve the detection of clinically significant prostate cancer (csPCa) while reducing unnecessary biopsies. This study aimed to evaluate csPCa detection rates using PI-RADS and PSAD, identify optimal PSAD cutoffs, and assess biopsy strategies to optimize csPCa detection and reduce unnecessary procedures within a South Korean cohort.
methodsThis multicenter retrospective study included 3117 biopsy-naïve patients from 2 tertiary hospitals in South Korea (2020-2025) who underwent magnetic resonance imaging-based transperineal prostate biopsy. Patients were stratified into PI-RADS groups (1-2, 3, 4-5) and PSAD categories (<0.10, 0.10-0.15, 0.15-0.20, and ≥0.20). Receiver-operating characteristic (ROC) curve analyses validated PSAD cut-offs, and biopsy strategies were compared for csPCa detection and biopsy avoidance.
resultsThe overall csPCa detection rate was 47.1%. PI-RADS 4-5 patients had high detection rates across all PSAD levels (20.1%-76.5%), while PI-RADS 1-2 and 3 patients with PSAD ≥ 0.15 showed elevated rates (15.2%-16.9% and 25.0%-35.7%, respectively). ROC curve analyses identified optimal PSAD cut-offs of 0.155 (area under the ROC curve (AUC), 0.708) for PI-RADS 1-2 and 0.145 (AUC, 0.749) for PI-RADS 3. The proposed strategy (PI-RADS ≥ 4 or PI-RADS 1-2 or 3 with PSAD ≥ 0.15) outperformed other strategies, avoiding 448 (14.4%) biopsies, missing 28 (1.9%) csPCa cases, and achieving a negative predictive value of 93.8%.
conclusionIntegrating PI-RADS with PSAD enhances risk stratification for csPCa, maintaining high diagnostic accuracy while reducing unnecessary procedures. Cite this article as: Lee SJ, Shin DH, Kim HY. Multicenter study on integrating prostate magnetic resonance imaging with prostate-specific antigen density for risk-adapted biopsy strategy in a South Korean cohort. Urol Res Pract. 2026, 52, 0014, doi: 10.5152/tud.2026.26014.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.